Fig. 1.

Effects of DTA-1 treatment of tumor-bearing TCRmini mice. Eight days after subcutaneous injection of the B16-Ep63K melanoma, mice (n = 12) were intravenously infused with a single dose (1 mg) of DTA-1. a Kinetics of tumor growth in DTA-1 treated and untreated (NT)—i.e., infused with normal rat Ig—mice. b Tumor weight at day 24. c The ratio of tumor-infiltrating T lymphocytes (TILs) to B16-Ep63K cells and d percentage of Tregs in total CD4⁺T cells in peripheral lymph nodes (pLN), draining lymph nodes (dLN), and TILs of untreated or DTA-1 treated mice